{"entity":{"id":"nct01829711","kind":"trial","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","aka":[],"tldr":"A phase 3 trial of Moxetumomab pasudotox in Leukaemia, run by MedImmune LLC, completed.","summary":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia is a phase 3 interventional study registered as NCT01829711 by MedImmune LLC, with 80 participants recorded, started 2013-04-29 and reaching its primary completion in 2017-05-24. Interventions recorded: Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox. Conditions recorded: Leukemia, Hairy Cell.\n\nLinked to the drug Moxetumomab pasudotox because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01829711","url":"https://clinicaltrials.gov/study/NCT01829711"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["moxetumomab-pasudotox"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01829711","phase":"3","setting":"A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia","sponsor":"MedImmune LLC","started":"2013-04-29","startedType":"actual","yearReported":2018,"enrolled":80,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Review","primary":true,"unit":"%","arms":[{"name":"Moxetumomab Pasudotox 40 µg/kg","n":80,"value":36.3,"note":"95% CI 25.8 to 47.8; Figures from the ClinicalTrials.gov results section (first posted 2018-08-27), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01829711?tab=results"},{"endpoint":"Percentage of Participants With Durable CR by Investigator's Assessment","primary":true,"unit":"%","arms":[{"name":"Moxetumomab Pasudotox 40 µg/kg","n":80,"value":48.8,"note":"95% CI 37.4 to 60.2; Figures from the ClinicalTrials.gov results section (first posted 2018-08-27), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01829711?tab=results"}]},"route":"/trials/nct01829711/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"moxetumomab-pasudotox","kind":"drug","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}